Strategies  ||| S:0 E:11 ||| NNS
for  ||| S:11 E:15 ||| IN
managing  ||| S:15 E:24 ||| VBG
fibromyalgia  ||| S:24 E:37 ||| VBN
The  ||| S:37 E:41 ||| DT
presentation  ||| S:41 E:54 ||| NN
of  ||| S:54 E:57 ||| IN
fibromyalgia  ||| S:57 E:70 ||| NN
is  ||| S:70 E:73 ||| VBZ
heterogeneous ||| S:73 E:86 ||| JJ
,  ||| S:86 E:88 ||| ,
and  ||| S:88 E:92 ||| CC
the  ||| S:92 E:96 ||| DT
treatment  ||| S:96 E:106 ||| NN
approach  ||| S:106 E:115 ||| NN
should  ||| S:115 E:122 ||| MD
be  ||| S:122 E:125 ||| VB
individualized  ||| S:125 E:140 ||| VBN
for  ||| S:140 E:144 ||| IN
each  ||| S:144 E:149 ||| DT
patient ||| S:149 E:156 ||| NN
,  ||| S:156 E:158 ||| ,
depending  ||| S:158 E:168 ||| VBG
on  ||| S:168 E:171 ||| IN
the  ||| S:171 E:175 ||| DT
severity  ||| S:175 E:184 ||| NN
of  ||| S:184 E:187 ||| IN
the  ||| S:187 E:191 ||| DT
patient ||| S:191 E:198 ||| NN
's  ||| S:198 E:201 ||| POS
pain ||| S:201 E:205 ||| NN
,  ||| S:205 E:207 ||| ,
the  ||| S:207 E:211 ||| DT
presence  ||| S:211 E:220 ||| NN
of  ||| S:220 E:223 ||| IN
other  ||| S:223 E:229 ||| JJ
symptoms  ||| S:229 E:238 ||| NNS
or  ||| S:238 E:241 ||| CC
comorbidities ||| S:241 E:254 ||| NN
,  ||| S:254 E:256 ||| ,
and  ||| S:256 E:260 ||| CC
the  ||| S:260 E:264 ||| DT
degree  ||| S:264 E:271 ||| NN
of  ||| S:271 E:274 ||| IN
functional  ||| S:274 E:285 ||| JJ
impairment ||| S:285 E:295 ||| NN
.  ||| S:295 E:297 ||| .
The  ||| S:297 E:301 ||| DT
management  ||| S:301 E:312 ||| NN
of  ||| S:312 E:315 ||| IN
fibromyalgia  ||| S:315 E:328 ||| NN
includes  ||| S:328 E:337 ||| VBZ
the  ||| S:337 E:341 ||| DT
identification  ||| S:341 E:356 ||| NN
and  ||| S:356 E:360 ||| CC
treatment  ||| S:360 E:370 ||| NN
of  ||| S:370 E:373 ||| IN
all  ||| S:373 E:377 ||| DT
pain  ||| S:377 E:382 ||| NN
sources  ||| S:382 E:390 ||| NNS
that  ||| S:390 E:395 ||| WDT
may  ||| S:395 E:399 ||| MD
be  ||| S:399 E:402 ||| VB
present  ||| S:402 E:410 ||| JJ
in  ||| S:410 E:413 ||| IN
addition  ||| S:413 E:422 ||| NN
to  ||| S:422 E:425 ||| TO
fibromyalgia ||| S:425 E:437 ||| VB
,  ||| S:437 E:439 ||| ,
such  ||| S:439 E:444 ||| JJ
as  ||| S:444 E:447 ||| IN
peripheral  ||| S:447 E:458 ||| JJ
pain  ||| S:458 E:463 ||| NN
generators  ||| S:463 E:474 ||| NNS
( ||| S:474 E:475 ||| -LRB-
e.g. ||| S:475 E:479 ||| NNP
,  ||| S:479 E:481 ||| ,
comorbid  ||| S:481 E:490 ||| JJ
osteoarthritis  ||| S:490 E:505 ||| NN
or  ||| S:505 E:508 ||| CC
neuropathic  ||| S:508 E:520 ||| JJ
pain ||| S:520 E:524 ||| NN
)  ||| S:524 E:526 ||| -RRB-
or  ||| S:526 E:529 ||| CC
visceral  ||| S:529 E:538 ||| JJ
pain  ||| S:538 E:543 ||| NN
( ||| S:543 E:544 ||| -LRB-
e.g. ||| S:544 E:548 ||| NNP
,  ||| S:548 E:550 ||| ,
comorbid  ||| S:550 E:559 ||| FW
irritable  ||| S:559 E:569 ||| FW
bowel  ||| S:569 E:575 ||| FW
syndrome ||| S:575 E:583 ||| FW
) ||| S:583 E:584 ||| -RRB-
.  ||| S:584 E:586 ||| .
It  ||| S:586 E:589 ||| PRP
is  ||| S:589 E:592 ||| VBZ
also  ||| S:592 E:597 ||| RB
important  ||| S:597 E:607 ||| JJ
to  ||| S:607 E:610 ||| TO
address  ||| S:610 E:618 ||| VB
other  ||| S:618 E:624 ||| JJ
symptoms  ||| S:624 E:633 ||| NNS
or  ||| S:633 E:636 ||| CC
disorders  ||| S:636 E:646 ||| NNS
that  ||| S:646 E:651 ||| WDT
commonly  ||| S:651 E:660 ||| RB
occur  ||| S:660 E:666 ||| VB
in  ||| S:666 E:669 ||| IN
patients  ||| S:669 E:678 ||| NNS
with  ||| S:678 E:683 ||| IN
fibromyalgia ||| S:683 E:695 ||| NN
,  ||| S:695 E:697 ||| ,
such  ||| S:697 E:702 ||| JJ
as  ||| S:702 E:705 ||| IN
fatigue ||| S:705 E:712 ||| NN
,  ||| S:712 E:714 ||| ,
sleep  ||| S:714 E:720 ||| JJ
disturbances ||| S:720 E:732 ||| NNS
,  ||| S:732 E:734 ||| ,
cognitive  ||| S:734 E:744 ||| JJ
impairment ||| S:744 E:754 ||| NN
,  ||| S:754 E:756 ||| ,
stiffness ||| S:756 E:765 ||| NN
,  ||| S:765 E:767 ||| ,
and  ||| S:767 E:771 ||| CC
mood  ||| S:771 E:776 ||| NN
or  ||| S:776 E:779 ||| CC
anxiety  ||| S:779 E:787 ||| NN
disorders ||| S:787 E:796 ||| NNS
.  ||| S:796 E:798 ||| .
Finally ||| S:798 E:805 ||| RB
,  ||| S:805 E:807 ||| ,
the  ||| S:807 E:811 ||| DT
treatment  ||| S:811 E:821 ||| NN
should  ||| S:821 E:828 ||| MD
strive  ||| S:828 E:835 ||| VB
to  ||| S:835 E:838 ||| TO
improve  ||| S:838 E:846 ||| VB
the  ||| S:846 E:850 ||| DT
patient ||| S:850 E:857 ||| NN
's  ||| S:857 E:860 ||| POS
function  ||| S:860 E:869 ||| NN
and  ||| S:869 E:873 ||| CC
global  ||| S:873 E:880 ||| JJ
health  ||| S:880 E:887 ||| NN
status ||| S:887 E:893 ||| NN
.  ||| S:893 E:895 ||| .
In  ||| S:895 E:898 ||| IN
most  ||| S:898 E:903 ||| JJS
cases ||| S:903 E:908 ||| NNS
,  ||| S:908 E:910 ||| ,
the  ||| S:910 E:914 ||| DT
management  ||| S:914 E:925 ||| NN
of  ||| S:925 E:928 ||| IN
fibromyalgia  ||| S:928 E:941 ||| NN
involves  ||| S:941 E:950 ||| VBZ
both  ||| S:950 E:955 ||| DT
pharmacologic  ||| S:955 E:969 ||| NN
and  ||| S:969 E:973 ||| CC
nonpharmacologic  ||| S:973 E:990 ||| JJ
treatments ||| S:990 E:1000 ||| NNS
.  ||| S:1000 E:1002 ||| .
This  ||| S:1002 E:1007 ||| DT
report  ||| S:1007 E:1014 ||| NN
provides  ||| S:1014 E:1023 ||| VBZ
an  ||| S:1023 E:1026 ||| DT
in-depth  ||| S:1026 E:1035 ||| JJ
review  ||| S:1035 E:1042 ||| NN
of  ||| S:1042 E:1045 ||| IN
randomized ||| S:1045 E:1055 ||| NN
,  ||| S:1055 E:1057 ||| ,
controlled  ||| S:1057 E:1068 ||| VBN
trials  ||| S:1068 E:1075 ||| NNS
for  ||| S:1075 E:1079 ||| IN
pharmacologic  ||| S:1079 E:1093 ||| NN
and  ||| S:1093 E:1097 ||| CC
nonpharmacologic  ||| S:1097 E:1114 ||| JJ
approaches  ||| S:1114 E:1125 ||| NNS
to  ||| S:1125 E:1128 ||| TO
fibromyalgia  ||| S:1128 E:1141 ||| VB
therapy ||| S:1141 E:1148 ||| NN
.  ||| S:1148 E:1150 ||| .
